Tags

Type your tag names separated by a space and hit enter

The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future.
Life Sci. 2020 Sep 15; 257:118142.LS

Abstract

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently defined as the worst pandemic disease. SARS-CoV-2 infects human cells via the binding of its S protein to the receptor angiotensin-converting enzyme (ACE2). The use of ACEIs/ARBs (RAAS inhibitors) regulates the renin-angiotensin-aldosterone system (RAAS) and may increase ACE2 expression. Considering the large use of ACEIs/ARBs in hypertensive patients, some professional groups are concerned about whether the use of RAAS inhibitors affects the risk of SARS-CoV-2 infection or the risk of severe illness and mortality in COVID-19 patients. In this review, we summarize preclinical and clinical studies to investigate whether the use of ACEIs/ARBs increases ACE2 expression in animals or patients. We also analyzed whether the use of these drugs affects the risk of SARS-CoV-2 infection, severe illness or mortality based on recent studies. Finally, the review suggests that current evidence does not support the concerns.

Authors+Show Affiliations

Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan, China; Hubei Key Laboratory of Cardiology, Wuhan, China.Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan, China; Hubei Key Laboratory of Cardiology, Wuhan, China.Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan, China; Hubei Key Laboratory of Cardiology, Wuhan, China.Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan, China; Hubei Key Laboratory of Cardiology, Wuhan, China. Electronic address: wanjun@whu.edu.cn.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32712300

Citation

Zhang, Jishou, et al. "The Interaction of RAAS Inhibitors With COVID-19: Current Progress, Perspective and Future." Life Sciences, vol. 257, 2020, p. 118142.
Zhang J, Wang M, Ding W, et al. The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future. Life Sci. 2020;257:118142.
Zhang, J., Wang, M., Ding, W., & Wan, J. (2020). The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future. Life Sciences, 257, 118142. https://doi.org/10.1016/j.lfs.2020.118142
Zhang J, et al. The Interaction of RAAS Inhibitors With COVID-19: Current Progress, Perspective and Future. Life Sci. 2020 Sep 15;257:118142. PubMed PMID: 32712300.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future. AU - Zhang,Jishou, AU - Wang,Menglong, AU - Ding,Wen, AU - Wan,Jun, Y1 - 2020/07/24/ PY - 2020/06/10/received PY - 2020/07/13/revised PY - 2020/07/21/accepted PY - 2020/7/28/pubmed PY - 2020/9/30/medline PY - 2020/7/27/entrez KW - ACE2 KW - COVID-19 KW - RAAS inhibitor KW - SARS-CoV-2 SP - 118142 EP - 118142 JF - Life sciences JO - Life Sci VL - 257 N2 - Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently defined as the worst pandemic disease. SARS-CoV-2 infects human cells via the binding of its S protein to the receptor angiotensin-converting enzyme (ACE2). The use of ACEIs/ARBs (RAAS inhibitors) regulates the renin-angiotensin-aldosterone system (RAAS) and may increase ACE2 expression. Considering the large use of ACEIs/ARBs in hypertensive patients, some professional groups are concerned about whether the use of RAAS inhibitors affects the risk of SARS-CoV-2 infection or the risk of severe illness and mortality in COVID-19 patients. In this review, we summarize preclinical and clinical studies to investigate whether the use of ACEIs/ARBs increases ACE2 expression in animals or patients. We also analyzed whether the use of these drugs affects the risk of SARS-CoV-2 infection, severe illness or mortality based on recent studies. Finally, the review suggests that current evidence does not support the concerns. SN - 1879-0631 UR - https://www.unboundmedicine.com/medline/citation/32712300/The_interaction_of_RAAS_inhibitors_with_COVID_19:_Current_progress_perspective_and_future_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0024-3205(20)30894-8 DB - PRIME DP - Unbound Medicine ER -